Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

66.67 +0.31 (+0.47%)
Streaming Delayed Price Updated: 10:52 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
From ViiV Healthcare
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021
Upgrades Piper Sandler upgraded the previous rating for Boston Properties Inc (NYSE:BXP) from Neutral to Overweight. Boston Properties earned $1.56 in the first quarter,... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Nymox Pharmaceutical (NASDAQ:NYMX... 
Via Benzinga
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2021
Upgrades B of A Securities upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Neutral to Buy. In the first quarter, Kosmos Energy showed an EPS of $0.08,... 
Via Benzinga
Halozyme Therapeutics Inc (HALO) Q1 2021 Earnings Call Transcript
HALO earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Earnings Outlook for Halozyme Therapeutics
On Monday, May 10, Halozyme Therapeutics (NASDAQ:HALO) will release its latest earnings report. Here is Benzinga's outlook for the company. Net Income, Earnings, And Earnings Per... 
Via Benzinga
Krystal Biotech Stock Sees Relative Strength Rating Jump To Noteworthy Territory
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. Krystal Biotech stock fits that bill. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2021
Upgrades For CEVA Inc (NASDAQ:CEVA), Barclays upgraded the previous rating of Equal-Weight to Overweight. For the first quarter, CEVA had an EPS of $0.01, compared to year... 
Via Benzinga
Biotech Cel-Sci Stock Joins Rank Of Stocks With RS Ratings Over 90
Cel-Sci shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Biotech Applied Molecular Transport Stock Earns Relative Strength Rating Upgrade
On Tuesday, Applied Molecular Transport stock reached an important technical milestone, seeing its Relative Strength Rating jump to 91 from 87. 
Via Investor's Business Daily
Arvinas Stock Clears Technical Benchmark With 80-Plus Relative Strength Rating
Arvinas shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84. 
Via Investor's Business Daily
Scholar Rock Stock Shows Market Leadership With Healthy Jump To 83 RS Rating
When looking for the best stocks to buy and watch, focus on those with rising relative price strength. Scholar Rock stock fits that bill. 
Via Investor's Business Daily
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.